Showing 15,221 - 15,230 of 15,526
of pharmaceuticals. Thus, we explore how changes in the technological regime and/or in the structure of demand may …
Persistent link: https://www.econbiz.de/10008788562
Project Portfolio Management (PPM) is a growing issue in both professional and academic circles. The typology of Cooper et al. (1998) has pictured the variety of PPM formalized approaches into four types (financial, strategic, scoring and “bubble diagram”). While the use of formalized...
Persistent link: https://www.econbiz.de/10008791076
In this paper, we address the issue of spurious correlation in the production of health in a systematic way. Spurious correlation entails the risk of linking health status to medical (and nonmedical) inputs when no links exist. This note first presents the bounds testing procedure as a method to...
Persistent link: https://www.econbiz.de/10008678138
pharmaceuticals. Using the Pharmaceutical Intellectual Property Protection (PIPP) Index, we find no evidence of a U …
Persistent link: https://www.econbiz.de/10008868094
We study the impact of product margins on pharmacies’ incentive to promote generics instead of brand-names. First, we construct a theoretical model where pharmacies can persuade patients with a brand-name prescription to purchase a generic version instead. We show that...
Persistent link: https://www.econbiz.de/10009019275
In this paper we focus on proximity as one of the main determinants of international collaboration in pharmaceutical research. We use various count data specifications of the gravity model to estimate the intensity of collaboration between pairs of countries as explained by the geographical,...
Persistent link: https://www.econbiz.de/10009141324
External referencing (ER) imposes a price cap for pharmaceuticals based on prices of identical products in foreign …
Persistent link: https://www.econbiz.de/10008793124
We study the impact of regulation on competition between brand-names and generics and pharmaceutical expenditures using a unique policy experiment in Norway, where reference pricing (RP) replaced price cap regulation in 2003 for a sub-sample of off-patent products. First, we construct a vertical...
Persistent link: https://www.econbiz.de/10008799730
This paper formulates an empirical methodology that evaluates pharmaceutical innovation in the American antidepressant market by quantifying patient welfare benefits from innovation. While evaluating pharmaceutical innovation in antidepressants, I uncover and address the moral hazard issue that...
Persistent link: https://www.econbiz.de/10008833204
Pharmaceutical markets are characterized by a high degree of innovation, complexity and uncertainty, especially markets of idiosyncratic symptomatolgy and response to treatment such as the antidepressant market. It may, therefore, be unreasonable to assume that consumers are aware of all...
Persistent link: https://www.econbiz.de/10008833205